Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Aging, Endothelial Dysfunction, Arterial Stiffness
Interventions: Fisetin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 65 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Endothelial Dysfunction
Interventions: Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Obesity & Overweight
Interventions: Exercise Program; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 20 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: 5g Cocoa Consumption, 10g Cocoa Consumption; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Derby, Connecticut • Boston, Massachusetts

Conditions: Corneal Transplantation
Interventions: EndoSaver™ Corneal Endothelium Delivery Instrument; Device
Lead sponsor: Ocular Systems, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Middle-aged Adults, Major Depressive Disorder
Interventions: MitoTempol, Lactated Ringer's (control); Drug
Lead sponsor: University of Delaware; Other
Eligibility: 40 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Peripheral Arterial Disease
Interventions: Pro-Omega, Omega 3 Fatty Acid; Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: Tetrahydrobiopterin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Insulin Resistance
Interventions: Exercise; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 19 Years to 35 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Matching Placebo, IW-1973; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Endothelial Dysfunction
Interventions: Centella Asiatica, Placebo Comparator; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 50 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
Interventions: Goodbelly, Placebo; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 89 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: GVHD,Acute
Interventions: blood sample; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Renal Cell Carcinoma
Interventions: Belzutifan, Zanzalintinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: San Francisco, California • Mineola, New York • New York, New York + 3 more

Conditions: Obesity, Pre-diabetes
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endothelial Dysfunction, Autonomic Dysfunction
Interventions: Resistance Exercise with Blood Flow Restriction, High-intensity Resistance Exercise; Other
Lead sponsor: Kent State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Chronic Renal Insufficiency
Interventions: Aerobic Exercise Training; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Systolic Heart Failure
Interventions: neuromodulation device, SHAM; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Obesity, Overweight
Interventions: Active Concord Grape Juice 12 oz per day, Placebo Grape Juice 12 oz per day; Other
Lead sponsor: Boston University; Other
Eligibility: 50 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Complications of Corneal Transplant
Interventions: Corneal donor storage in Optisol GS media solution, Life 4°C solution for cornea storage; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Cleveland, Ohio + 1 more

Conditions: Exudative Age Related Macular Degeneration
Interventions: Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin; Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Fisetin to Improve Vascular Function in Older Adults

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

Effects of Exercise on Lipids and Endothelial Function in Youth

Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension

Corneal Endothelium Delivery Instrument

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

Effects of Tetrahydrobiopterin on Blood Pressure

The Effects of Altering Physical Activity on Cardiometabolic Health

Blood Flow and Pain Crises in People With Sickle Cell Disease

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Centella Asiatica in Older Adults

Acute Probiotic Supplementation and Endothelial Function

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Upper- and Lower-body Resistance Exercise With and Without Blood Flow Restriction on Hemodynamics and Vascular Function

Exercise and Vascular Function in Chronic Kidney Disease

Neuromodulation of Inflammation and Endothelial Function

Effect of Concord Grape Juice on Endothelial Function

Life 4°C Versus Optisol in Corneal Storage Media

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets